Strengthening Global Presence
Grindeks, the leading pharmaceutical company in the Baltics, is reinforcing its international presence by expanding into new export markets. For the first time, its products will be available in Panama, further strengthening its footprint across Latin America, Asia, Europe, and beyond.
The company already exports to diverse regions, including Chile, Mexico, Australia, Singapore, and the Philippines, as well as most European countries. Additionally, its active pharmaceutical ingredients (APIs) are supplied to Japan, South Korea, and the United States, underscoring Grindeks’ commitment to global healthcare.
Trusted Partner for International Health Organisations
As a prequalified supplier for the World Health Organization (WHO), Grindeks plays a vital role in international health initiatives. It supplies injectable medications to key organisations such as UNFPA and UNICEF, which distribute these products to countries in Africa, including Kenya, Tanzania, Liberia, Sudan, Burkina Faso, and Zimbabwe.
Kirovs Lipmans, Chairman of the Council of Grindeks, stated: “Expanding into new export markets reflects our dedication to improving global healthcare. Through continuous investment in innovation, quality, and regulatory excellence, we ensure Grindeks remains a trusted name worldwide. Our presence in diverse regions demonstrates our commitment to providing effective and accessible medicines to those who need them most.”
Commitment to Quality and Global Health
Grindeks’ Chief Executive Officer, Ph.D. Juris Hmeļņickis, highlighted the company’s dedication to export growth: “For us, export is more than business it is an opportunity to contribute to global health and well-being. Every market we enter symbolises our mission to improve lives through high-quality medicines. Expanding into diverse regions, including Europe, Asia, Latin America, and Africa, allows us to address critical healthcare needs while meeting international regulatory standards.”
He further emphasised the challenges involved: “Navigating global markets requires adapting to regulatory complexities, cultural differences, and logistical challenges. These factors drive us to enhance our efficiency, innovation, and resilience, ensuring that Grindeks’ trusted products reach patients worldwide.”
Keys to Export Success
Grindeks’ success in expanding its global reach can be attributed to several key factors:
- Meeting International Standards – Grindeks ensures that all medicines comply with stringent global safety and efficacy regulations, making them suitable for export.
- Strong Logistics and Shelf Life – The company’s medicines have a 2–5 year shelf life, allowing distribution to remote locations such as Tanzania and Zimbabwe.
- Targeting High-Demand Regions – Many of Grindeks’ products serve countries with limited access to essential medicines, addressing critical healthcare gaps.
Overcoming Challenges in Global Markets
Expanding into new markets is not without obstacles. Countries such as China, Japan, the Philippines, Brazil, Malaysia, and Chile have strict regulatory frameworks that require compliance with unique standards. Adapting to these regulations demands significant time and investment.
Additionally, cultural and operational differences from language barriers to time zones require a tailored approach to business relationships. Despite these challenges, Grindeks has demonstrated adaptability and resilience, successfully meeting international standards and growing its presence.
A Leader in Global Pharmaceuticals
Grindeks’ global competitiveness continues to rise. According to the IQVIA Global Market analysis, the company ranked 299th out of 5,768 pharmaceutical companies in Europe in 2023, highlighting its strong industry position.
With a vision to become one of the top 100 global pharmaceutical companies, Grindeks remains committed to innovation, quality, and expansion, ensuring that life-saving medicines reach patients across the world.